AbbVie Financial Results
AbbVie reported third-quarter 2026 net revenues of $17.404 billion, a 10.3% increase driven by strong growth in its immunology and neuroscience portfolios. The company raised its full-year 2026 adjusted EPS guidance and announced a 5.2% increase to its quarterly dividend starting in February 2027.
- Term
- Q3 2026
“AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio. We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.”
Robert A. Michael, chairman and chief executive officer